<?xml version="1.0"?>
<presentation title="01 Yu Kyung Cho" width="810.0000000" height="540.0000000" thmbWidth="78.0000000" thmbHeight="52.0000000" frameRate="24.0000000" looping="0" startingSlideShow="" pptVersion="2010" type="compound" hasExternalAudio="0" uid="{5FF308B2-B98A-4E74-8B64-E86D41BD2B1E}">
	<presenters>
		<presenter name="Yu Kyung Cho" title="The Catholic University of korea" email="" web="" phone="" photoAssetId="">
			<bio>EUS guided tissue acquisition: subepithelial lesion</bio>
		</presenter>
	</presenters>
	<references/>
	<soundAssets>
		<soundAsset id="sndAsset0" src="sound1.mp3" embedded="0" size="246536" duration="8803"/>
		<soundAsset id="sndAsset1" src="sound2.mp3" embedded="0" size="643702" duration="22988"/>
		<soundAsset id="sndAsset2" src="sound3.mp3" embedded="0" size="903359" duration="32261"/>
		<soundAsset id="sndAsset3" src="sound4.mp3" embedded="0" size="986011" duration="35213"/>
		<soundAsset id="sndAsset4" src="sound5.mp3" embedded="0" size="602742" duration="21525"/>
		<soundAsset id="sndAsset5" src="sound6.mp3" embedded="0" size="559588" duration="19984"/>
		<soundAsset id="sndAsset6" src="sound7.mp3" embedded="0" size="577874" duration="20637"/>
		<soundAsset id="sndAsset7" src="sound8.mp3" embedded="0" size="932616" duration="33306"/>
		<soundAsset id="sndAsset8" src="sound9.mp3" embedded="0" size="295542" duration="10553"/>
		<soundAsset id="sndAsset9" src="sound10.mp3" embedded="0" size="986742" duration="35239"/>
		<soundAsset id="sndAsset10" src="sound11.mp3" embedded="0" size="1449005" duration="51749"/>
		<soundAsset id="sndAsset11" src="sound12.mp3" embedded="0" size="512045" duration="18286"/>
		<soundAsset id="sndAsset12" src="sound13.mp3" embedded="0" size="483519" duration="17267"/>
		<soundAsset id="sndAsset13" src="sound14.mp3" embedded="0" size="446216" duration="15935"/>
		<soundAsset id="sndAsset14" src="sound15.mp3" embedded="0" size="999176" duration="35683"/>
		<soundAsset id="sndAsset15" src="sound16.mp3" embedded="0" size="878491" duration="31373"/>
		<soundAsset id="sndAsset16" src="sound17.mp3" embedded="0" size="699291" duration="24973"/>
		<soundAsset id="sndAsset17" src="sound18.mp3" embedded="0" size="712456" duration="25443"/>
		<soundAsset id="sndAsset18" src="sound19.mp3" embedded="0" size="403794" duration="14420"/>
		<soundAsset id="sndAsset19" src="sound20.mp3" embedded="0" size="316022" duration="11285"/>
		<soundAsset id="sndAsset20" src="sound21.mp3" embedded="0" size="977234" duration="34900"/>
		<soundAsset id="sndAsset21" src="sound22.mp3" embedded="0" size="931885" duration="33280"/>
		<soundAsset id="sndAsset22" src="sound23.mp3" embedded="0" size="741714" duration="26488"/>
		<soundAsset id="sndAsset23" src="sound24.mp3" embedded="0" size="821439" duration="29336"/>
		<soundAsset id="sndAsset24" src="sound25.mp3" embedded="0" size="714651" duration="25522"/>
		<soundAsset id="sndAsset25" src="sound26.mp3" embedded="0" size="862399" duration="30798"/>
		<soundAsset id="sndAsset26" src="sound27.mp3" embedded="0" size="747565" duration="26697"/>
		<soundAsset id="sndAsset27" src="sound28.mp3" embedded="0" size="303588" duration="10841"/>
		<soundAsset id="sndAsset28" src="sound29.mp3" embedded="0" size="546422" duration="19513"/>
		<soundAsset id="sndAsset29" src="sound30.mp3" embedded="0" size="484251" duration="17293"/>
		<soundAsset id="sndAsset30" src="sound31.mp3" embedded="0" size="689051" duration="24607"/>
		<soundAsset id="sndAsset31" src="sound32.mp3" embedded="0" size="547885" duration="19566"/>
		<soundAsset id="sndAsset32" src="sound33.mp3" embedded="0" size="623222" duration="22256"/>
		<soundAsset id="sndAsset33" src="sound34.mp3" embedded="0" size="630536" duration="22518"/>
		<soundAsset id="sndAsset34" src="sound35.mp3" embedded="0" size="672228" duration="24007"/>
		<soundAsset id="sndAsset35" src="sound36.mp3" embedded="0" size="1086948" duration="38818"/>
	</soundAssets>
	<sharedAssetsLibrary src="assets.swf"/>
	<graphicAssets>
		<graphicAsset id="imgAsset0" src="thmb1.swf" embedded="0"/>
		<graphicAsset id="imgAsset1" src="thmb2.swf" embedded="0"/>
		<graphicAsset id="imgAsset2" src="thmb3.swf" embedded="0"/>
		<graphicAsset id="imgAsset3" src="thmb4.swf" embedded="0"/>
		<graphicAsset id="imgAsset4" src="thmb5.swf" embedded="0"/>
		<graphicAsset id="imgAsset5" src="thmb6.swf" embedded="0"/>
		<graphicAsset id="imgAsset6" src="thmb7.swf" embedded="0"/>
		<graphicAsset id="imgAsset7" src="thmb8.swf" embedded="0"/>
		<graphicAsset id="imgAsset8" src="thmb9.swf" embedded="0"/>
		<graphicAsset id="imgAsset9" src="thmb10.swf" embedded="0"/>
		<graphicAsset id="imgAsset10" src="thmb11.swf" embedded="0"/>
		<graphicAsset id="imgAsset11" src="thmb12.swf" embedded="0"/>
		<graphicAsset id="imgAsset12" src="thmb13.swf" embedded="0"/>
		<graphicAsset id="imgAsset13" src="thmb14.swf" embedded="0"/>
		<graphicAsset id="imgAsset14" src="thmb15.swf" embedded="0"/>
		<graphicAsset id="imgAsset15" src="thmb16.swf" embedded="0"/>
		<graphicAsset id="imgAsset16" src="thmb17.swf" embedded="0"/>
		<graphicAsset id="imgAsset17" src="thmb18.swf" embedded="0"/>
		<graphicAsset id="imgAsset18" src="thmb19.swf" embedded="0"/>
		<graphicAsset id="imgAsset19" src="thmb20.swf" embedded="0"/>
		<graphicAsset id="imgAsset20" src="thmb21.swf" embedded="0"/>
		<graphicAsset id="imgAsset21" src="thmb22.swf" embedded="0"/>
		<graphicAsset id="imgAsset22" src="thmb23.swf" embedded="0"/>
		<graphicAsset id="imgAsset23" src="thmb24.swf" embedded="0"/>
		<graphicAsset id="imgAsset24" src="thmb25.swf" embedded="0"/>
		<graphicAsset id="imgAsset25" src="thmb26.swf" embedded="0"/>
		<graphicAsset id="imgAsset26" src="thmb27.swf" embedded="0"/>
		<graphicAsset id="imgAsset27" src="thmb28.swf" embedded="0"/>
		<graphicAsset id="imgAsset28" src="thmb29.swf" embedded="0"/>
		<graphicAsset id="imgAsset29" src="thmb30.swf" embedded="0"/>
		<graphicAsset id="imgAsset30" src="thmb31.swf" embedded="0"/>
		<graphicAsset id="imgAsset31" src="thmb32.swf" embedded="0"/>
		<graphicAsset id="imgAsset32" src="thmb33.swf" embedded="0"/>
		<graphicAsset id="imgAsset33" src="thmb34.swf" embedded="0"/>
		<graphicAsset id="imgAsset34" src="thmb35.swf" embedded="0"/>
		<graphicAsset id="imgAsset35" src="thmb36.swf" embedded="0"/>
	</graphicAssets>
	<playlists/>
	<narration>
		<audioTracks>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset0">
				<startTimestamp slideIndex="0" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="0" stepIndex="0" timeOffset="8.7749996"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset1">
				<startTimestamp slideIndex="1" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="1" stepIndex="0" timeOffset="22.9559994"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset2">
				<startTimestamp slideIndex="2" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="2" stepIndex="0" timeOffset="32.2319984"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset3">
				<startTimestamp slideIndex="3" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="3" stepIndex="0" timeOffset="35.1679993"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset4">
				<startTimestamp slideIndex="4" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="4" stepIndex="0" timeOffset="21.4880000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset5">
				<startTimestamp slideIndex="5" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="5" stepIndex="0" timeOffset="19.9529991"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset6">
				<startTimestamp slideIndex="6" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="6" stepIndex="0" timeOffset="20.5869999"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset7">
				<startTimestamp slideIndex="7" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="7" stepIndex="0" timeOffset="33.2669983"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset8">
				<startTimestamp slideIndex="8" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="8" stepIndex="0" timeOffset="10.5100000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset9">
				<startTimestamp slideIndex="9" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="9" stepIndex="0" timeOffset="35.2019997"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset10">
				<startTimestamp slideIndex="10" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="10" stepIndex="0" timeOffset="51.7179985"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset11">
				<startTimestamp slideIndex="11" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="11" stepIndex="0" timeOffset="18.2520000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset12">
				<startTimestamp slideIndex="12" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="12" stepIndex="0" timeOffset="17.2169991"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset13">
				<startTimestamp slideIndex="13" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="13" stepIndex="0" timeOffset="15.8830000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset14">
				<startTimestamp slideIndex="14" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="14" stepIndex="0" timeOffset="35.6360000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset15">
				<startTimestamp slideIndex="15" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="15" stepIndex="0" timeOffset="31.3309994"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset16">
				<startTimestamp slideIndex="16" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="16" stepIndex="0" timeOffset="24.9249992"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset17">
				<startTimestamp slideIndex="17" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="17" stepIndex="0" timeOffset="25.3920000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset18">
				<startTimestamp slideIndex="18" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="18" stepIndex="0" timeOffset="14.3809996"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset19">
				<startTimestamp slideIndex="19" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="19" stepIndex="0" timeOffset="11.2449999"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset20">
				<startTimestamp slideIndex="20" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="20" stepIndex="0" timeOffset="34.8680000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset21">
				<startTimestamp slideIndex="21" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="21" stepIndex="0" timeOffset="33.2330000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset22">
				<startTimestamp slideIndex="22" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="22" stepIndex="0" timeOffset="26.4599991"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset23">
				<startTimestamp slideIndex="23" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="23" stepIndex="0" timeOffset="29.2959995"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset24">
				<startTimestamp slideIndex="24" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="24" stepIndex="0" timeOffset="25.4920000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset25">
				<startTimestamp slideIndex="25" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="25" stepIndex="0" timeOffset="30.7639999"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset26">
				<startTimestamp slideIndex="26" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="26" stepIndex="0" timeOffset="26.6599998"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset27">
				<startTimestamp slideIndex="27" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="27" stepIndex="0" timeOffset="10.8109999"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset28">
				<startTimestamp slideIndex="28" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="28" stepIndex="0" timeOffset="19.4860000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset29">
				<startTimestamp slideIndex="29" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="29" stepIndex="0" timeOffset="17.2509995"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset30">
				<startTimestamp slideIndex="30" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="30" stepIndex="0" timeOffset="24.5580000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset31">
				<startTimestamp slideIndex="31" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="31" stepIndex="0" timeOffset="19.5200000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset32">
				<startTimestamp slideIndex="32" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="32" stepIndex="0" timeOffset="22.2220000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset33">
				<startTimestamp slideIndex="33" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="33" stepIndex="0" timeOffset="22.4890000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset34">
				<startTimestamp slideIndex="34" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="34" stepIndex="0" timeOffset="23.9570000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset35">
				<startTimestamp slideIndex="35" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="35" stepIndex="0" timeOffset="38.7719994"/>
			</audioTrack>
		</audioTracks>
	</narration>
	<settings>
		<navigation>
			<keyboard enabled="1">
				<actions>
					<action name="playPause">
						<shortcut code="32" control="0" shift="0"/>
					</action>
					<action name="nextSlide">
						<shortcut code="34" control="0" shift="0"/>
					</action>
					<action name="previousSlide">
						<shortcut code="33" control="0" shift="0"/>
					</action>
					<action name="nextStep">
						<shortcut code="13" control="0" shift="0"/>
					</action>
					<action name="previousStep">
						<shortcut code="13" control="0" shift="1"/>
					</action>
					<action name="firstSlide">
						<shortcut code="36" control="1" shift="0"/>
					</action>
					<action name="lastSlide">
						<shortcut code="35" control="1" shift="0"/>
					</action>
					<action name="lastViewedSlide">
						<shortcut code="8" control="0" shift="0"/>
					</action>
					<action name="slideStart">
						<shortcut code="36" control="0" shift="0"/>
					</action>
					<action name="slideEnd">
						<shortcut code="35" control="0" shift="0"/>
					</action>
					<action name="seekForward">
						<shortcut code="39" control="0" shift="0"/>
					</action>
					<action name="seekBackward">
						<shortcut code="37" control="0" shift="0"/>
					</action>
					<action name="volumeUp">
						<shortcut code="38" control="0" shift="0"/>
					</action>
					<action name="volumeDown">
						<shortcut code="40" control="0" shift="0"/>
					</action>
					<action name="toggleFullscreen">
						<shortcut code="70" control="1" shift="0"/>
					</action>
				</actions>
			</keyboard>
			<mouse enabled="1" target="step"/>
			<gesture zoom="1"/>
		</navigation>
		<skin>
			<colorSettings>
				<color id="button.content.normal">#FFFFFF</color>
				<color id="button.content.over">#FFFFFF</color>
				<color id="button.face.normal">#777777</color>
				<color id="button.face.over">#575757</color>
				<color id="companyLogo.background">#FFFFFF</color>
				<color id="hyperlink">#097CE7</color>
				<color id="listItem.face.over">#E8E8E8</color>
				<color id="listItem.face.pressed">#6E6E6E</color>
				<color id="listItem.label.over">#000000</color>
				<color id="listItem.label.pressed">#FFFFFF</color>
				<color id="listItem.label.visited">#A1A1A1</color>
				<color id="page.background">#8A8A8A</color>
				<color id="panel.background">#F7F7F7</color>
				<color id="panel.text">#323232</color>
				<color id="player.background">#D4D4D4</color>
				<color id="popup.background">#FFFFFF</color>
				<color id="progress.background">#6E6E6E</color>
				<color id="progress.loading">#D0D0D0</color>
				<color id="progress.playback">#A1A1A1</color>
				<color id="text">#4D4D4D</color>
			</colorSettings>
			<controlPanelSettings>
				<visible>true</visible>
				<showOutline>false</showOutline>
				<showPlayPause>true</showPlayPause>
				<showRewind>true</showRewind>
				<showVolumeControl>true</showVolumeControl>
				<showCCButton>false</showCCButton>
				<showPrevButton>true</showPrevButton>
				<showNextButton>true</showNextButton>
				<showSlideOnlyButton>true</showSlideOnlyButton>
				<progressBar>
					<visible>true</visible>
					<enabled>true</enabled>
					<showLabels>true</showLabels>
					<mode>slideTimeline</mode>
				</progressBar>
				<navigationMode>bySlides</navigationMode>
			</controlPanelSettings>
			<titlePanelSettings>
				<showLogo>false</showLogo>
				<visible>true</visible>
				<buttons>
					<button type="attachments" visible="false"/>
					<button type="presenterInfo" visible="false"/>
					<button type="markerTools" visible="true"/>
					<button type="notes" visible="false"/>
					<button type="outline" visible="false"/>
				</buttons>
			</titlePanelSettings>
			<outlinePanelSettings>
				<numberEntries>true</numberEntries>
				<highlightViewedEntries>true</highlightViewedEntries>
				<thumbnails>true</thumbnails>
				<search>true</search>
				<multilevel>true</multilevel>
			</outlinePanelSettings>
			<sidePanelSettings>
				<showAtLeft>true</showAtLeft>
				<showLogo>false</showLogo>
				<showPresenterInfo>true</showPresenterInfo>
				<showPresenterVideo>false</showPresenterVideo>
				<visible>true</visible>
				<tabsPanel>
					<showOutline>true</showOutline>
					<showNotes>false</showNotes>
				</tabsPanel>
			</sidePanelSettings>
		</skin>
		<appearance fullScreen="1" showSlidePreloader="1"/>
		<playback autoStart="1" syncWithVideoNarration="1" enableVideoControl="1" resumePresentationPlayback="always"/>
	</settings>
	<slides embedded="0">
		<slide index="0" title="EUS guided tissue acquisition: subepithelial lesion" titleNormalized="eus guided tissue acquisition: subepithelial lesion" src="slide1.swf" size="489333" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset0" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="8.7739996"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>EUS guided tissue acquisition: subepithelial lesion 
Yu Kyung Cho
The Catholic University of Korea, Seoul, Korea</text>
		</slide>
		<slide index="1" title="small EUS-suspected gastric GISTs" titleNormalized="small eus-suspected gastric gists" src="slide2.swf" size="110756" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset1" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="22.9549994"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>small EUS-suspected gastric GISTs</text>
		</slide>
		<slide index="2" title="EUS- guided tissue sampling in SELs" titleNormalized="eus- guided tissue sampling in sels" src="slide3.swf" size="3167" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset2" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="32.2309984"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>EUS- guided tissue sampling in SELs 
In some subepithelial lesions, EUS characteristics are not typical to diagnose
Pathologic confirmation is necessary in some SMTs , especially mass in 3rd layer, even in &lt; 2cm sized small tumor.
 EUS- FNA, deep biopsy, endoscopic resection : clinician’s preference and lesions</text>
		</slide>
		<slide index="3" title="83/M ampulla submucosal tumor 1.5X1.5cm" titleNormalized="83/m ampulla submucosal tumor 1.5x1.5cm" src="slide4.swf" size="502765" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset3" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="35.1669993"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>83/M ampulla submucosal tumor 1.5X1.5cm
Cytology :some neutrophils, lymphocytes and a few larva of parasites. 
Bx : Strongyloidiasis</text>
		</slide>
		<slide index="4" title="45/ F stomach antrum 2X2cm" titleNormalized="45/ f stomach antrum 2x2cm" src="slide5.swf" size="440104" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset4" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="21.4870009"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>45/ F stomach antrum 2X2cm 
inflammatory fibrous tumor</text>
		</slide>
		<slide index="5" title="28/F 2X1cm,gastric cardia" titleNormalized="28/f 2x1cm,gastric cardia" src="slide6.swf" size="438293" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset5" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="19.9519991"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>28/F 2X1cm,gastric cardia 
Heterotopic pancreas</text>
		</slide>
		<slide index="6" title="1.6X0.7cm esophageal SELs" titleNormalized="1.6x0.7cm esophageal sels" src="slide7.swf" size="372666" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset6" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="20.5859999"/>
			</animationSteps>
			<notes>EUS-FNB procedure 는 다음과 같이 진행되었는데,
먼저 모든 procedure는 한명의 endosonographer를 통해 시행되었습니다. (이전에 70회 이상의 FNA procedure를 시행한)
Radial echoendoscope을 사용하여 lesion을 mapping하고 lorigin layer를 확인하였고,
(방사형으로 주사방식이 초음파 진동자가 내시경 축에 수직으로 360도의 환상의 영상을 얻는 방식으로 넓은 범위의 단층상을 쉽게 얻을 수 있으나, 천자침은 단지 하나의 점상 에코로만 관찰되며 그 끝을 눈으로 확인할 수 없 다. )
Linear array echoendoscope로 7.5메가헤르츠의 imaging frequency로 needle biopsy 를 guide하였습니다. 컬러 플로우 도플러 울트라사운드를 통해 vascular structure를 제외한 뒤 19게이지 procore needle을 사용하여 병변에 puncture하였습니다.</notes>
			<notesNormalized>eus-fnb procedure 는 다음과 같이 진행되었는데,
먼저 모든 procedure는 한명의 endosonographer를 통해 시행되었습니다. (이전에 70회 이상의 fna procedure를 시행한)
radial echoendoscope을 사용하여 lesion을 mapping하고 lorigin layer를 확인하였고,
(방사형으로 주사방식이 초음파 진동자가 내시경 축에 수직으로 360도의 환상의 영상을 얻는 방식으로 넓은 범위의 단층상을 쉽게 얻을 수 있으나, 천자침은 단지 하나의 점상 에코로만 관찰되며 그 끝을 눈으로 확인할 수 없 다. )
linear array echoendoscope로 7.5메가헤르츠의 imaging frequency로 needle biopsy 를 guide하였습니다. 컬러 플로우 도플러 울트라사운드를 통해 vascular structure를 제외한 뒤 19게이지 procore needle을 사용하여 병변에 puncture하였습니다.</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;EUS-FNB procedure 는 다음과 같이 진행되었는데,&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;먼저 모든 procedure는 한명의 endosonographer를 통해 시행되었습니다. (이전에 70회 이상의 FNA procedure를 시행한)&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;Radial echoendoscope을 사용하여 lesion을 mapping하고 lorigin layer를 확인하였고,&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;(방사형으로 주사방식이 초음파 진동자가 내시경 축에 수직으로 360도의 환상의 영상을 얻는 방식으로 넓은 범위의 단층상을 쉽게 얻을 수 있으나, 천자침은 단지 하나의 점상 에코로만 관찰되며 그 끝을 눈으로 확인할 수 없 다. )&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;Linear array echoendoscope로 7.5메가헤르츠의 imaging frequency로 needle biopsy 를 guide하였습니다. 컬러 플로우 도플러 울트라사운드를 통해 vascular structure를 제외한 뒤 19게이지 procore needle을 사용하여 병변에 puncture하였습니다.&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>1.6X0.7cm esophageal SELs




leiomyoma</text>
		</slide>
		<slide index="7" title="EUS guided tissue sampling : Core biopsy or cytology" titleNormalized="eus guided tissue sampling : core biopsy or cytology" src="slide8.swf" size="168160" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset7" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="33.2659983"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>EUS guided tissue sampling : Core biopsy or cytology
More tissue
- reduce the need for ROSE (rapid onsite cytologic evaluation)
- more diagnostic
Tissue architecture or IHC are necessary in the diagnosis of
 - lymphoma
 - GIST, autoimmune pancreatitis
False (+) in cytologic interpretation:5-7%</text>
		</slide>
		<slide index="8" title="“ the best” samples" titleNormalized="“ the best” samples" src="slide9.swf" size="2867" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset8" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="10.5090002"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>“ the best” samples
Cellular sample
Least bloody
Adequate quantity




</text>
		</slide>
		<slide index="9" title="Factors affecting outcome of EUS-FNA" titleNormalized="factors affecting outcome of eus-fna" src="slide10.swf" size="3530" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset9" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="35.2009997"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Factors affecting outcome of EUS-FNA
Needle : lesion and locations
FNA technique : suction, use of stylet, number of needle pass

Sampling : standard suction wet suction, capillary method , door-knocking
Rapid on- site cytologic evaluation (ROSE)

Dig Endosc 2012;24:358-63
Endoscopic Ultasound 2014;3:98-108</text>
		</slide>
		<slide index="10" title="Needle" titleNormalized="needle" src="slide11.swf" size="173779" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset10" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="51.7169985"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Needle 
Standard needle
 for FNA
Flex 19 G needle
EXPECT 
Core needle
 for FNB
19,22,25 G Echotip
Shark core
19,22,25 G Procore 
20G procore</text>
		</slide>
		<slide index="11" title="Overall outcomes :EUS-FNA of Subepithelial Tumors" titleNormalized="overall outcomes :eus-fna of subepithelial tumors" src="slide12.swf" size="16523" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset11" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="18.2510008"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Overall outcomes :EUS-FNA of Subepithelial Tumors</text>
		</slide>
		<slide index="12" title="Tissue biopsy samples using standard 22G needle" titleNormalized="tissue biopsy samples using standard 22g needle" src="slide13.swf" size="161306" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset12" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="17.2159991"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Tissue biopsy samples using standard 22G needle</text>
		</slide>
		<slide index="13" title="Tissue biopsy samples using standard 19 G needle" titleNormalized="tissue biopsy samples using standard 19 g needle" src="slide14.swf" size="264785" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset13" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="15.8820004"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Tissue biopsy samples using standard 19 G needle</text>
		</slide>
		<slide index="14" title="The needle selection: standard 22 G vs. 25 G" titleNormalized="the needle selection: standard 22 g vs. 25 g" src="slide15.swf" size="8657" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset14" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="35.6350016"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>The needle selection: standard 22 G vs. 25 G 
Over all 22 G= 25 G</text>
		</slide>
		<slide index="15" title="Needle size" titleNormalized="needle size" src="slide16.swf" size="13912" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset15" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="31.3299994"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Needle size
Needle size has only a limited effect on outcomes in EUS-FNA
Selection of needle depends on the location
Affolter KE et al. Dig Dis Sci 2013
Transduodenal 
FNA : 25 G 
Transgastric FNA 22 ,25 
Tranesophagageal FNA 22 ,25 
 
Angulated Difficulty</text>
		</slide>
		<slide index="16" title="Suction" titleNormalized="suction" src="slide17.swf" size="9412" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset16" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="24.9239992"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Suction
No role for suction</text>
		</slide>
		<slide index="17" title="Suction during EUS-FNA" titleNormalized="suction during eus-fna" src="slide18.swf" size="3372" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset17" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="25.3910002"/>
			</animationSteps>
			<notes>Subepithelial tumor (SET) originating in gastric proper muscle layer  includes neoplastic tumors with malignant potential and non malignant potential. 
Differentiating these tumors is crucial for clinical management, as a even small gastrointestinal tumor(GIST) has malignant potential.
NCCN guide line, Europian guide line and Korean guide line for PM layer tumor recommend surgical resection of tumors larger than 2cm even without pathologic diagnosis.
Recommended management strategy for small PM layer tumors       (&lt;2cm) is periodic follow up examination with uncertain interval. 



Subepithelial tumor 는 GI tract 에서 발생하는 neoplastic 과 non-neoplastic condition 을 모두 포함하는 용어로서 
이들중 일부는 malignant potential 을 가지고 있기에 clinical management 를 결정함에 있어 병변을 differentiation 하는 것은 중요한 일입니다. 

하지만 크기가 작고 증상이 없는 SET 에 대하여는 현재까지 명확한 mangement guideline 이 없습니다. 다만</notes>
			<notesNormalized>subepithelial tumor (set) originating in gastric proper muscle layer includes neoplastic tumors with malignant potential and non malignant potential. 
differentiating these tumors is crucial for clinical management, as a even small gastrointestinal tumor(gist) has malignant potential.
nccn guide line, europian guide line and korean guide line for pm layer tumor recommend surgical resection of tumors larger than 2cm even without pathologic diagnosis.
recommended management strategy for small pm layer tumors (&lt;2cm) is periodic follow up examination with uncertain interval. 



subepithelial tumor 는 gi tract 에서 발생하는 neoplastic 과 non-neoplastic condition 을 모두 포함하는 용어로서 
이들중 일부는 malignant potential 을 가지고 있기에 clinical management 를 결정함에 있어 병변을 differentiation 하는 것은 중요한 일입니다. 

하지만 크기가 작고 증상이 없는 set 에 대하여는 현재까지 명확한 mangement guideline 이 없습니다. 다만</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="20"&gt;Subepithelial tumor (SET) originating in gastric proper muscle layer  includes neoplastic tumors with malignant potential and non malignant potential. &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="20"&gt;Differentiating these tumors is crucial for clinical management, as a even small gastrointestinal tumor(GIST) has malignant potential.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="20"&gt;NCCN guide line, Europian guide line and Korean guide line for PM layer tumor recommend surgical resection of tumors larger than 2cm even without pathologic diagnosis.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="20"&gt;Recommended management strategy for small PM layer tumors       (&amp;lt;2cm) is periodic follow up examination with uncertain interval. &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;Subepithelial tumor 는 GI tract 에서 발생하는 neoplastic 과 non-neoplastic condition 을 모두 포함하는 용어로서 &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;이들중 일부는 malignant potential 을 가지고 있기에 clinical management 를 결정함에 있어 병변을 differentiation 하는 것은 중요한 일입니다. &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;하지만 크기가 작고 증상이 없는 SET 에 대하여는 현재까지 명확한 mangement guideline 이 없습니다. 다만&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>may increase the size of the sample, blood dilution may decrease the diagnostic yield.
improves diagnosis of malignancy in patients with solid masses but not in patients with lymphadenopathy 

ESGE recommend using suction for EUS-FNA of solid masses/cystic lesions and not using suction for EUS-FNA of lymph nodes (Recommendation grade C).

No advantage of suction 











Suction during EUS-FNA
Endoscopy 2012;44:190-205Gastrointest Endosc2012;76::328-35
</text>
		</slide>
		<slide index="18" title="Stylet" titleNormalized="stylet" src="slide19.swf" size="12374" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset18" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="14.3799996"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Stylet 
Gimeno-García AZ, et al.. Dig Endosc. 2013</text>
		</slide>
		<slide index="19" title="Stylet" titleNormalized="stylet" src="slide20.swf" size="8387" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset19" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="11.2439999"/>
			</animationSteps>
			<notes>Subepithelial tumor (SET) originating in gastric proper muscle layer  includes neoplastic tumors with malignant potential and non malignant potential. 
Differentiating these tumors is crucial for clinical management, as a even small gastrointestinal tumor(GIST) has malignant potential.
NCCN guide line, Europian guide line and Korean guide line for PM layer tumor recommend surgical resection of tumors larger than 2cm even without pathologic diagnosis.
Recommended management strategy for small PM layer tumors       (&lt;2cm) is periodic follow up examination with uncertain interval. 



Subepithelial tumor 는 GI tract 에서 발생하는 neoplastic 과 non-neoplastic condition 을 모두 포함하는 용어로서 
이들중 일부는 malignant potential 을 가지고 있기에 clinical management 를 결정함에 있어 병변을 differentiation 하는 것은 중요한 일입니다. 

하지만 크기가 작고 증상이 없는 SET 에 대하여는 현재까지 명확한 mangement guideline 이 없습니다. 다만</notes>
			<notesNormalized>subepithelial tumor (set) originating in gastric proper muscle layer includes neoplastic tumors with malignant potential and non malignant potential. 
differentiating these tumors is crucial for clinical management, as a even small gastrointestinal tumor(gist) has malignant potential.
nccn guide line, europian guide line and korean guide line for pm layer tumor recommend surgical resection of tumors larger than 2cm even without pathologic diagnosis.
recommended management strategy for small pm layer tumors (&lt;2cm) is periodic follow up examination with uncertain interval. 



subepithelial tumor 는 gi tract 에서 발생하는 neoplastic 과 non-neoplastic condition 을 모두 포함하는 용어로서 
이들중 일부는 malignant potential 을 가지고 있기에 clinical management 를 결정함에 있어 병변을 differentiation 하는 것은 중요한 일입니다. 

하지만 크기가 작고 증상이 없는 set 에 대하여는 현재까지 명확한 mangement guideline 이 없습니다. 다만</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="20"&gt;Subepithelial tumor (SET) originating in gastric proper muscle layer  includes neoplastic tumors with malignant potential and non malignant potential. &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="20"&gt;Differentiating these tumors is crucial for clinical management, as a even small gastrointestinal tumor(GIST) has malignant potential.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="20"&gt;NCCN guide line, Europian guide line and Korean guide line for PM layer tumor recommend surgical resection of tumors larger than 2cm even without pathologic diagnosis.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="20"&gt;Recommended management strategy for small PM layer tumors       (&amp;lt;2cm) is periodic follow up examination with uncertain interval. &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;Subepithelial tumor 는 GI tract 에서 발생하는 neoplastic 과 non-neoplastic condition 을 모두 포함하는 용어로서 &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;이들중 일부는 malignant potential 을 가지고 있기에 clinical management 를 결정함에 있어 병변을 differentiation 하는 것은 중요한 일입니다. &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;하지만 크기가 작고 증상이 없는 SET 에 대하여는 현재까지 명확한 mangement guideline 이 없습니다. 다만&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Stylet
Using the needle stylet does not seem to impact EUS-FNA sample quality and results
insufficient evidence to recommend

Europian Society of Gastrointestinal Endoscopy (ESGE) Technical Guideline. 
Endoscopy 2012;44:190-205.
Gastrointest Endosc2009;70:254-61











</text>
		</slide>
		<slide index="20" title="Number of needle pass" titleNormalized="number of needle pass" src="slide21.swf" size="9584" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset20" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="34.8670000"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Number of needle pass
&gt; 5 pass, diagnostic yield is similar to that of EUS-TCB

&gt; 3 passes vs &lt;3 passes in Pancreas ca and SET
 Diagnostic accuracy; 90.0%(108/120) vs 78.0%(39/50), p&lt;0.05
 Digestive Endoscopy 2012;24:358-363
Lymph nodes generally required a lower number of needle passes three needle passes were sufficient
Endoscopy 2010;42:324-6.</text>
		</slide>
		<slide index="21" title="HOW many passes if on site cytologic evaluation is not available?" titleNormalized="how many passes if on site cytologic evaluation is not available?" src="slide22.swf" size="3644" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset21" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="33.2320017"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>HOW many passes if on site cytologic evaluation is not available?
In submucosal tumors, the accuracy of EUS-FNA increased gradually with each consequent pass to reach a plateau after the fourth pass
A retrospective study, 112 upper GI subepithelial lesions. EUS-FNA, over all diagnostic yield of 83.9%, :high diagnostic yield was obtained with a mean of 5.3 FNA passes.
In a Japanese study. 141 patients, a mean of 2.5 ± 0.7 passes with 22-G needle, sample adequacy of 83%, better for lesions &gt;2 cm than for those with a smaller diameter.</text>
		</slide>
		<slide index="22" title="Standard FNA vs. Fanning FNA" titleNormalized="standard fna vs. fanning fna" src="slide23.swf" size="45049" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset22" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="26.4589991"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Standard FNA vs. Fanning FNA 
RCT of Standard vs. Fanning FNA
Standard N=26
Fanning N=26
First pass diagnosis
57.7%
85.7%
P=0.03
Endoscopy 2013; 45: 445–450
 moving the needle at different directions inside the mass. a fan-like motion</text>
		</slide>
		<slide index="23" title="Capillary techniques" titleNormalized="capillary techniques" src="slide24.swf" size="4695" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset23" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="29.2949995"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Capillary techniques 
Nakai Y ,Dig Dis Sci 2014
Moving back stylet with slow - pull manner
Difference significant for 25 G, not 22G Needle 
</text>
		</slide>
		<slide index="24" title="Wet suction" titleNormalized="wet suction" src="slide25.swf" size="234544" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset24" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="25.4910006"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Wet suction 
Attam R: GIE 2015
Wet suction
Conventional suction
P
Mean cellularity
1.83(+/-0.79)
1.44(+/-0.769)
&lt;0.003
Diagnostic yield %
85.5
75.2
&lt;0.035
Loading syringe with saline before puncture lesions, then applyng negative suction with saline during FNA
N=117 lesions : lesions including pancreas 54%</text>
		</slide>
		<slide index="25" title="How many to and fro movement ?" titleNormalized="how many to and fro movement ?" src="slide26.swf" size="7861" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset25" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="30.7629999"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>How many to and fro movement ? 
Suction (N=94) 
No suction (N=99)
Celluar
Blood
Yield
10
26.2%
51.2%
59.5%
15
38.1%
50%
71.4%
20
34.5%
52.4%
72.6%
25
32.3%
53.8%
69.2%
Na S DDW2013 Ab 404</text>
		</slide>
		<slide index="26" title="ROSE (rapid on site cytologic evaluation)" titleNormalized="rose (rapid on site cytologic evaluation)" src="slide27.swf" size="44117" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset26" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="26.6589998"/>
			</animationSteps>
			<notes>Addition of EUS guided FNA and On site  pathologist to EUS- FNB increases proxedure time but not to diagnostic accuracy
No additive benefit with initial EUS- FNA </notes>
			<notesNormalized>addition of eus guided fna and on site pathologist to eus- fnb increases proxedure time but not to diagnostic accuracy
no additive benefit with initial eus- fna</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;Addition of EUS guided FNA and On site  pathologist to EUS- FNB increases proxedure time but not to diagnostic accuracy&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;No additive benefit with initial EUS- FNA &lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>ROSE (rapid on site cytologic evaluation)
International survey
Korea : ROSE is not available in most hospitals 
Time consuming
Reimbursement for cytologist
Some studies reported no additional benefit about diagnostic yield</text>
		</slide>
		<slide index="27" title="Core needle" titleNormalized="core needle" src="slide28.swf" size="176788" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset27" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="10.8099999"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Core needle
Procore
Quick-Core (TCB)
Shark Core</text>
		</slide>
		<slide index="28" title="Trucut biopsy" titleNormalized="trucut biopsy" src="slide29.swf" size="102538" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset28" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="19.4850001"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Trucut biopsy
The Quick-Core®, 19 G needle
Diagnostic accuracy : 52% - 100%
Yield : (50-100%) 
Stiff : The worst performances during transduodenal approach
Failed to reach widespread use
 technical difficulty 
 the relative lack of advantages over standard FNA needles,
</text>
		</slide>
		<slide index="29" title="EUS-TCB of Subepithelial Tumors" titleNormalized="eus-tcb of subepithelial tumors" src="slide30.swf" size="14665" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset29" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="17.2499995"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>EUS-TCB of Subepithelial Tumors</text>
		</slide>
		<slide index="30" title="Procore needle" titleNormalized="procore needle" src="slide31.swf" size="115585" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset30" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="24.5570006"/>
			</animationSteps>
			<notes>Subepithelial tumor (SET) originating in gastric proper muscle layer  includes neoplastic tumors with malignant potential and non malignant potential. 
Differentiating these tumors is crucial for clinical management, as a even small gastrointestinal tumor(GIST) has malignant potential.
NCCN guide line, Europian guide line and Korean guide line for PM layer tumor recommend surgical resection of tumors larger than 2cm even without pathologic diagnosis.
Recommended management strategy for small PM layer tumors       (&lt;2cm) is periodic follow up examination with uncertain interval. 



Subepithelial tumor 는 GI tract 에서 발생하는 neoplastic 과 non-neoplastic condition 을 모두 포함하는 용어로서 
이들중 일부는 malignant potential 을 가지고 있기에 clinical management 를 결정함에 있어 병변을 differentiation 하는 것은 중요한 일입니다. 

하지만 크기가 작고 증상이 없는 SET 에 대하여는 현재까지 명확한 mangement guideline 이 없습니다. 다만</notes>
			<notesNormalized>subepithelial tumor (set) originating in gastric proper muscle layer includes neoplastic tumors with malignant potential and non malignant potential. 
differentiating these tumors is crucial for clinical management, as a even small gastrointestinal tumor(gist) has malignant potential.
nccn guide line, europian guide line and korean guide line for pm layer tumor recommend surgical resection of tumors larger than 2cm even without pathologic diagnosis.
recommended management strategy for small pm layer tumors (&lt;2cm) is periodic follow up examination with uncertain interval. 



subepithelial tumor 는 gi tract 에서 발생하는 neoplastic 과 non-neoplastic condition 을 모두 포함하는 용어로서 
이들중 일부는 malignant potential 을 가지고 있기에 clinical management 를 결정함에 있어 병변을 differentiation 하는 것은 중요한 일입니다. 

하지만 크기가 작고 증상이 없는 set 에 대하여는 현재까지 명확한 mangement guideline 이 없습니다. 다만</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="20"&gt;Subepithelial tumor (SET) originating in gastric proper muscle layer  includes neoplastic tumors with malignant potential and non malignant potential. &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="20"&gt;Differentiating these tumors is crucial for clinical management, as a even small gastrointestinal tumor(GIST) has malignant potential.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="20"&gt;NCCN guide line, Europian guide line and Korean guide line for PM layer tumor recommend surgical resection of tumors larger than 2cm even without pathologic diagnosis.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="20"&gt;Recommended management strategy for small PM layer tumors       (&amp;lt;2cm) is periodic follow up examination with uncertain interval. &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;Subepithelial tumor 는 GI tract 에서 발생하는 neoplastic 과 non-neoplastic condition 을 모두 포함하는 용어로서 &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;이들중 일부는 malignant potential 을 가지고 있기에 clinical management 를 결정함에 있어 병변을 differentiation 하는 것은 중요한 일입니다. &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;하지만 크기가 작고 증상이 없는 SET 에 대하여는 현재까지 명확한 mangement guideline 이 없습니다. 다만&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Procore needle 






Hallowed lateral opening of varying length and distance from the needle tip, depending on the needle size
Reverse bevel technique : Hook and cut the tissue and entrapping it into the needle
19, 22, 25 gauge, Flexibility</text>
		</slide>
		<slide index="31" title="EUS-FNB tissue acquisition in upper GI SELs" titleNormalized="eus-fnb tissue acquisition in upper gi sels" src="slide32.swf" size="4590" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset31" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="19.5190005"/>
			</animationSteps>
			<notes>Procore needle을 사용한 이전 연구들은,
최근에 아산에서 2cm 이상의 gastric subepithelial tumor에 대해 22게이지 procore needle을 사용한 결과를 발표하였는데요, 
총 78명의 환자가 enroll되었고 puncture의 성공률은 98.7%였고, 진단적 가치가 있었던 것은  81.8 퍼센트에서였고 이 진단적인 검체중 97퍼센트가 core biopsy tissue가 포함된 경우였습니다.  
결과로 보면 GIST가 39퍼센트로 가장 많았고, leiomyoma가 26%, 그외에 heterotopic pancreas, schwannoma, cancer, inflammatory pseudotumor가 있는 경우였습니다. 

또한 19게이지procore needle을 사용하여 intra- and extra-intestinal lesions에 대한 진단률을 본 검사에서는,
FNB를 통해 98%에서 합병증 없이 검체를 얻었고 ,  Technical하게 성공적으로 채취한 모든 sample은 pathological evaluation을 하기에 적합한 sample들이었고 19G needle의 제한점으로 생각된 transduodenal sampling 역시 높은 94%의 성공률을 보였습니다. 
또한 histologic examination 을 위한 조직의 적절성은 90%였고 진단적 정확도는 모든 병변에서 86%로 파악되어 그 효용성을 보여주었습니다.
 



---------------------------------------------------------------------------------------------------------------------

Puncture success raet = sample adequacy
Diagnostic sufficiency rate = 검체로 진단이 나온 비율

Procore needle을 사용한 이전 연구들은,
최근에 아산에서 2cm 이상의 gastric subepithelial tumor에 대해 22게이지 procore needle을 사용한 결과를 발표하였는데요, 
총 78명의 환자가 enroll되었고 fundus에 위치한 병변에서 technichal failure가 있어 성공률은 98.7%였고, 
얻은 검체가 진단적 가치가 있었던 것은  81.8 퍼센트에서였고,  이 진단적인 검체중 97퍼센트가 core biopsy tissue가 포함된 경우였습니다.  
결과로 보면 GIST가 39퍼센트로 가장 많았고, leiomyoma가 26%, 그외에 heterotopic pancreas, schwannoma, cancer, inflammatory pseudotumor가 있는 경우였습니다. 

하지만 이 경우는 2cm보다 크기가 큰 경우로서, 앞서 알고리즘에서 보셨듯이 일반적으로 크기가 3cm이상이면 수술을 먼저 고려하고, 3cm보다 작은 병변에서 histology를 생각하게 되기 때문에,
크기가 작은 subepithelial tumor에서 histologic evaluation이 invasive procedure를 줄이고 manage를 하는데 도움이 될 수 있다고 생각됩니다. 
그러나 이러한 작은 병변에 대한 procore needle을 사용한 FNB 에 대한 study는 아직 부족한 상태입니다. 

또한 19게이지procore needle을 사용하여 intra- and extra-intestinal lesions의 진단을 하는 것에 대해서, 
 Iglesias-Garcia et al 에서  large multicenter study를 통해 평가하였는데 
114명의 heterogeneous lesions을 가진 109명의 환자에서 FNB를 통해 98%인 112 케이스에서 합병증 없이 검체를 얻었고 ,  Technical하게 성공적으로 채취한 모든 sample은 pathological evaluation을 하기에 적합한 sample들이었고 연구내에서 transduodenal sampling전체를 따졌을때 역시 높은 94%의 성공률을 보였습니다. 
또한 histologic examination 을 위한 조직의 적절성은 90%였습니다. 진단적 정확도는 모든 병변에서 86%로 파악되어 그 효용성을 보여주었습니다.
 </notes>
			<notesNormalized>procore needle을 사용한 이전 연구들은,
최근에 아산에서 2cm 이상의 gastric subepithelial tumor에 대해 22게이지 procore needle을 사용한 결과를 발표하였는데요, 
총 78명의 환자가 enroll되었고 puncture의 성공률은 98.7%였고, 진단적 가치가 있었던 것은 81.8 퍼센트에서였고 이 진단적인 검체중 97퍼센트가 core biopsy tissue가 포함된 경우였습니다. 
결과로 보면 gist가 39퍼센트로 가장 많았고, leiomyoma가 26%, 그외에 heterotopic pancreas, schwannoma, cancer, inflammatory pseudotumor가 있는 경우였습니다. 

또한 19게이지procore needle을 사용하여 intra- and extra-intestinal lesions에 대한 진단률을 본 검사에서는,
fnb를 통해 98%에서 합병증 없이 검체를 얻었고 ,  technical하게 성공적으로 채취한 모든 sample은 pathological evaluation을 하기에 적합한 sample들이었고 19g needle의 제한점으로 생각된 transduodenal sampling 역시 높은 94%의 성공률을 보였습니다. 
또한 histologic examination 을 위한 조직의 적절성은 90%였고 진단적 정확도는 모든 병변에서 86%로 파악되어 그 효용성을 보여주었습니다.
 



---------------------------------------------------------------------------------------------------------------------

puncture success raet = sample adequacy
diagnostic sufficiency rate = 검체로 진단이 나온 비율

procore needle을 사용한 이전 연구들은,
최근에 아산에서 2cm 이상의 gastric subepithelial tumor에 대해 22게이지 procore needle을 사용한 결과를 발표하였는데요, 
총 78명의 환자가 enroll되었고 fundus에 위치한 병변에서 technichal failure가 있어 성공률은 98.7%였고, 
얻은 검체가 진단적 가치가 있었던 것은 81.8 퍼센트에서였고, 이 진단적인 검체중 97퍼센트가 core biopsy tissue가 포함된 경우였습니다. 
결과로 보면 gist가 39퍼센트로 가장 많았고, leiomyoma가 26%, 그외에 heterotopic pancreas, schwannoma, cancer, inflammatory pseudotumor가 있는 경우였습니다. 

하지만 이 경우는 2cm보다 크기가 큰 경우로서, 앞서 알고리즘에서 보셨듯이 일반적으로 크기가 3cm이상이면 수술을 먼저 고려하고, 3cm보다 작은 병변에서 histology를 생각하게 되기 때문에,
크기가 작은 subepithelial tumor에서 histologic evaluation이 invasive procedure를 줄이고 manage를 하는데 도움이 될 수 있다고 생각됩니다. 
그러나 이러한 작은 병변에 대한 procore needle을 사용한 fnb 에 대한 study는 아직 부족한 상태입니다. 

또한 19게이지procore needle을 사용하여 intra- and extra-intestinal lesions의 진단을 하는 것에 대해서, 
 iglesias-garcia et al 에서  large multicenter study를 통해 평가하였는데 
114명의 heterogeneous lesions을 가진 109명의 환자에서 fnb를 통해 98%인 112 케이스에서 합병증 없이 검체를 얻었고 ,  technical하게 성공적으로 채취한 모든 sample은 pathological evaluation을 하기에 적합한 sample들이었고 연구내에서 transduodenal sampling전체를 따졌을때 역시 높은 94%의 성공률을 보였습니다. 
또한 histologic examination 을 위한 조직의 적절성은 90%였습니다. 진단적 정확도는 모든 병변에서 86%로 파악되어 그 효용성을 보여주었습니다.
</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;Procore needle을 사용한 이전 연구들은,&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;최근에 아산에서 2cm 이상의 gastric subepithelial tumor에 대해 22게이지 procore needle을 사용한 결과를 발표하였는데요, &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;총 78명의 환자가 enroll되었고 puncture의 성공률은 98.7%였고, 진단적 가치가 있었던 것은  81.8 퍼센트에서였고 이 진단적인 검체중 97퍼센트가 core biopsy tissue가 포함된 경우였습니다.  &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;결과로 보면 GIST가 39퍼센트로 가장 많았고, leiomyoma가 26%, 그외에 heterotopic pancreas, schwannoma, cancer, inflammatory pseudotumor가 있는 경우였습니다. &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;또한 19게이지procore needle을 사용하여 intra- and extra-intestinal lesions에 대한 진단률을 본 검사에서는,&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;FNB를 통해 98%에서 합병증 없이 검체를 얻었고 ,  Technical하게 성공적으로 채취한 모든 sample은 pathological evaluation을 하기에 적합한 sample들이었고 19G needle의 제한점으로 생각된 transduodenal sampling 역시 높은 94%의 성공률을 보였습니다. &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;또한 histologic examination 을 위한 조직의 적절성은 90%였고 진단적 정확도는 모든 병변에서 86%로 파악되어 그 효용성을 보여주었습니다.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt; &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;---------------------------------------------------------------------------------------------------------------------&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;Puncture success raet = sample adequacy&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;Diagnostic sufficiency rate = 검체로 진단이 나온 비율&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;Procore needle을 사용한 이전 연구들은,&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;최근에 아산에서 2cm 이상의 gastric subepithelial tumor에 대해 22게이지 procore needle을 사용한 결과를 발표하였는데요, &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;총 78명의 환자가 enroll되었고 fundus에 위치한 병변에서 technichal failure가 있어 성공률은 98.7%였고, &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;얻은 검체가 진단적 가치가 있었던 것은  81.8 퍼센트에서였고,  이 진단적인 검체중 97퍼센트가 core biopsy tissue가 포함된 경우였습니다.  &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;결과로 보면 GIST가 39퍼센트로 가장 많았고, leiomyoma가 26%, 그외에 heterotopic pancreas, schwannoma, cancer, inflammatory pseudotumor가 있는 경우였습니다. &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;하지만 이 경우는 2cm보다 크기가 큰 경우로서, 앞서 알고리즘에서 보셨듯이 일반적으로 크기가 3cm이상이면 수술을 먼저 고려하고, 3cm보다 작은 병변에서 histology를 생각하게 되기 때문에,&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;크기가 작은 subepithelial tumor에서 histologic evaluation이 invasive procedure를 줄이고 manage를 하는데 도움이 될 수 있다고 생각됩니다. &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;그러나 이러한 작은 병변에 대한 procore needle을 사용한 FNB 에 대한 study는 아직 부족한 상태입니다. &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;또한 19게이지procore needle을 사용하여 intra- and extra-intestinal lesions의 진단을 하는 것에 대해서, &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt; Iglesias-Garcia &lt;i&gt;et al 에서 &lt;/i&gt; large multicenter study를 통해 평가하였는데 &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;114명의 heterogeneous lesions을 가진 109명의 환자에서 FNB를 통해 98%인 112 케이스에서 합병증 없이 검체를 얻었고 ,  Technical하게 성공적으로 채취한 모든 sample은 pathological evaluation을 하기에 적합한 sample들이었고 연구내에서 transduodenal sampling전체를 따졌을때 역시 높은 94%의 성공률을 보였습니다. &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;또한 histologic examination 을 위한 조직의 적절성은 90%였습니다. 진단적 정확도는 모든 병변에서 86%로 파악되어 그 효용성을 보여주었습니다.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt; &lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>EUS-FNB tissue acquisition in upper GI SELs
Author
year
Pt No
Needle
Lesion size
( &gt; 2cm)
Puncture success 
(%)
tissue acquisition
(%)
Diagnostic sufficiency
(%)
Iglesias-Garcia 
2011
109
19G
35.1 ± 18.7 mm
98.2
89
GH Kim. 
2014
12
22G
3.2 ± 1.7 cm
100
92
75
Lee M. 
2015
43
22G
GI SETs 
&gt;2 cm
100
94.5
86</text>
		</slide>
		<slide index="32" title="Procore 22G vs. standard needle 22G" titleNormalized="procore 22g vs. standard needle 22g" src="slide33.swf" size="77149" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset32" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="22.2210001"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Procore 22G vs. standard needle 22G 
Diagnostic yield ( IHC with tissue core) is better in Procore groups.
Scand J Gastroenterol 2015</text>
		</slide>
		<slide index="33" title="Procore vs. standard needle :meta-analysis" titleNormalized="procore vs. standard needle :meta-analysis" src="slide34.swf" size="126157" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset33" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="22.4880003"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Procore vs. standard needle :meta-analysis 
 No difference</text>
		</slide>
		<slide index="34" title="fork-tip needle Shark Core (SC)" titleNormalized="fork-tip needle shark core (sc)" src="slide35.swf" size="163564" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset34" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="23.9560007"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>fork-tip needle Shark Core (SC)
a novel fork-tip needle, the Shark Core (SC) (Medtronic Corp) 
the ability to obtain true histology and reduce the number of passes needed to obtain adequate material compared with conventional EUS-FNA.
GIE2015</text>
		</slide>
		<slide index="35" title="Summary" titleNormalized="summary" src="slide36.swf" size="3165" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset35" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="38.7709994"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Summary
EUS- tissue sampling in SELs
22 = 25 G needle (25 G for transduodenal pass?)
Suction/ stylet- insufficient evidence to recommend
&gt; 3-5 pass for SELs. &gt; 3 LNs 
Specialized needles for more tissue histology</text>
		</slide>
	</slides>
</presentation>
